Oncology Drugs - Haiti

Haiti

The market for Oncology Drugs market in Haiti is expected to achieve a revenue of US$20.15m by the year 2024.
It is projected that the revenue will exhibit a compound annual growth rate (CAGR 2024-2029) of 6.53%, leading to a market volume of US$27.64m by 2029.
When compared globally, United States is anticipated to generate the highest revenue of US$103,900.00m in 2024.
Despite the challenges of limited healthcare infrastructure and resources, Haiti is witnessing a growing demand for affordable and accessible oncology drugs.

Key regions: France, Europe, United Kingdom, Brazil, India

Market

Region

Region comparison

Currency

Analyst Opinion

The Haitian Oncology Drugs market has been experiencing significant growth in recent years.

Customer preferences: The demand for Oncology Drugs in Haiti has been on the rise due to a growing awareness of cancer and its treatment options. Patients are increasingly seeking out better quality drugs to treat their conditions, and are more willing to pay for them.

Trends in the market: One of the major trends in the Haitian Oncology Drugs market is the increasing availability of generic drugs. This has led to a decrease in prices, making the drugs more accessible to a wider range of patients. Another trend is the growing popularity of immunotherapy drugs, which are used to boost the body's natural defenses against cancer.

Local special circumstances: Haiti is a country that faces many challenges, including a lack of access to healthcare facilities and a shortage of medical professionals. This has led to a reliance on imported drugs, which can be expensive and difficult to obtain. However, there are efforts being made to improve the healthcare system and increase access to essential medicines, including Oncology Drugs.

Underlying macroeconomic factors: Haiti is one of the poorest countries in the Western Hemisphere, with a low GDP and high levels of poverty. However, the country has been experiencing slow but steady economic growth in recent years, which has led to an increase in healthcare spending. Additionally, there has been a growing interest in investing in the Haitian market, which has led to an increase in the availability of drugs and medical supplies.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.